david chiswell chairman nonexecutive kymab ltd timesjavascript is disabled market profiles login sign up login sign up   edit person david chiswell chairman nonexecutive at kymab ltd location add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop david chiswell chairman nonexecutive at kymab ltd location add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop after a career as a research scientist in both the uk and the us and nine years working in scientific management at amersham international david was cofounder of cambridge antibody technology cat in  he was responsible for operational management from  to  including as ceo from  to  cat listed on the london stock exchange in april  and nasdaq in june  since leaving cat in march  david has been focusing on the development of early stage biotechnology companies including positions as nonexecutive chairman of sosei ltd arrow therapeutics ltd and daniolabs ltd and as a director of arakis ltd david is currently executive chairman of albireo ltd and is an advisor to phase partners david is a past chairman of the uk’s bioindustry association bia in  he was awarded the obe by hm queen for services to the biotechnology industry  companies in career na related markets na colleagues na related investments alias na industry rd in biotech environmental and various industries no marketing product yet tags na topics of influence web site na careers achievements investments related people edit view all david chiswellcareer  sep kymab ltd chairman nonexecutive jun nabriva therapeutics director non executive  albireo chairman competencies edit view all david chiswelleducation  hm the queen biotechnology industry edit david chiswellachievements and recognitions add milestone no milestones has been recorded for david chiswell edit david chiswelllinks add link no links has been recorded for david chiswell david chiswellinvestmentsacquisitions no investments has been recorded for david chiswell david chiswellinvestments representing others no investment reps has been recorded for david chiswell david chiswellrelated people view all peers  ali behbahani nonexecutive director of adaptimmune george lowell nonexecutive director of biondvax andreas niethammer executive director of nantkwest view all david chiswellrecommended market profiles  telemedicine  or more employees  companies social media marketing chiefmarteccom    employees  companies big data universe list of lists  or more employees  companies aggregated marketing technology  or more employees 26 companies shared economy landscape jeremiah owyang  or more employees  companies inside sales landscape  or more employees 6 companies chiswell david  the wall street transcript david chiswell david chiswell bsc phd is the chief executive officer of cambridge antibody technology group plc a founder of cat dr chiswell has been responsible for the operational management of cat from its inception he joined the board in december  and took on the role of chief executive officer in  prior to cat he spent nine years at amersham international plc where his main responsibilities included product development and research management dr chiswell research experience was gained at the mrc institute of virology in glasgow the department of immunology and microbiology at ucla california and in the department of tumour virology at the imperial cancer research fund in london related interviewsdavid chiswell  cambridge antibody technology group plc catloctober  2 cartlatest newsall american usc footbal player joseph m boskovich jr now picks all american value stocks for his clientspaul hogan picks tech dividend growers microchip technology nasdaqmchp xilinx nasdaqxlnx and versum materials nysevsm gallons of water to produce a mcdonalds nysemcd quarter pounder how will investors profitthe wall street transcript is a completely unique resource for investors and business researchersover  ceo equity analyst and money manager interviewssubscribe nowsign up for newsletter weekly email with new indepth interviews email most popular interviewsbuilding diversified portfolios with quality global equitiesgregory d padillaalberto jimenez crespo published july   in investing strategiescompanies covered amzn  aapl mu whr kimbera gs vod ppg shw viv pey buy 2building accountability and avoiding mistakes through the decision processdean pagonis published july   in investing strategiescompanies covered cmp sbh amzn ulta cvs lrlcy kmb www sdf buy 2finding optimal balance sheets by utilizing high yield market expertisezach miller published july   in investing strategiescompanies covered lsxmk siri bll chtr armk buy 2most popular reportsinvesting strategies published july 2 buy wireless communications  telecom published july  buy investing strategies published july  buy  top company interviews register for a free account to gain greater access to the wall street transcript right now ceo interviewsinterview with the president and ceo lumos networks corp nasdaqlmosinterview with the corporate vp of business development strategy and investor relations dsp group inc nasdaqdspginterview with the ceo and director tactile systems technology inc nasdaqtcmd sector roundtablesnatural gas weighs heavy on ep nearterm prospectsroundtable forumoptimism despite uncertainty in forprofit educationroundtable foruma shift in focus to natural gas from oil money manager interviewsbuilding diversified portfolios with quality global equitiesbuilding accountability and avoiding mistakes through the decision processfinding optimal balance sheets by utilizing high yield market expertise analyst interviewsanalyzing the secular drivers within communications infrastructure and telecomsatellite companies benefiting from growth in data trafficincreased focus on content as consumers shift to digital consumption subscribe today since 6  the wall street transcript 6 terms and conditions privacy policy   httpswwwtwstcomwpadminadminajaxphp pin it on pinterest share this twitter facebook google gmail linkedin × join now for free already a member first name last name email address  create new account or create an account with a social network join with facebook join with twitter join with google username or email address  password  loginjoin now  forgot password or login using a social network log in with facebook log in with twitter log in with google chiswell david  the wall street transcript david chiswell david chiswell is chief executive officer of cambridge antibody technology group mr chiswell was a founder of cat and was appointed as a director in december  he has been responsible for operational management since the foundation previously he spent nine years at amersham international plc where he held a number of posts combining responsibilities for product development and research management prior to moving into the commercial sector in  he gained research experience in the field of molecular retrovirology at the mrc institute of virology in glasgow the department of immunology and microbiology at ucla in california and in the department of tumour virology at the imperial cancer research fund in london related interviewsdavid chiswell  cambridge antibody technology plc catfebruary 2  cartlatest newsall american usc footbal player joseph m boskovich jr now picks all american value stocks for his clientspaul hogan picks tech dividend growers microchip technology nasdaqmchp xilinx nasdaqxlnx and versum materials nysevsm gallons of water to produce a mcdonalds nysemcd quarter pounder how will investors profitthe wall street transcript is a completely unique resource for investors and business researchersover  ceo equity analyst and money manager interviewssubscribe nowsign up for newsletter weekly email with new indepth interviews email most popular interviewsbuilding diversified portfolios with quality global equitiesgregory d padillaalberto jimenez crespo published july   in investing strategiescompanies covered amzn  aapl mu whr kimbera gs vod ppg shw viv pey buy 2building accountability and avoiding mistakes through the decision processdean pagonis published july   in investing strategiescompanies covered cmp sbh amzn ulta cvs lrlcy kmb www sdf buy 2finding optimal balance sheets by utilizing high yield market expertisezach miller published july   in investing strategiescompanies covered lsxmk siri bll chtr armk buy 2most popular reportsinvesting strategies published july 2 buy wireless communications  telecom published july  buy investing strategies published july  buy  top company interviews register for a free account to gain greater access to the wall street transcript right now ceo interviewsinterview with the president and ceo lumos networks corp nasdaqlmosinterview with the corporate vp of business development strategy and investor relations dsp group inc nasdaqdspginterview with the ceo and director tactile systems technology inc nasdaqtcmd sector roundtablesnatural gas weighs heavy on ep nearterm prospectsroundtable forumoptimism despite uncertainty in forprofit educationroundtable foruma shift in focus to natural gas from oil money manager interviewsbuilding diversified portfolios with quality global equitiesbuilding accountability and avoiding mistakes through the decision processfinding optimal balance sheets by utilizing high yield market expertise analyst interviewsanalyzing the secular drivers within communications infrastructure and telecomsatellite companies benefiting from growth in data trafficincreased focus on content as consumers shift to digital consumption subscribe today since 6  the wall street transcript 6 terms and conditions privacy policy   httpswwwtwstcomwpadminadminajaxphp pin it on pinterest share this twitter facebook google gmail linkedin × join now for free already a member first name last name email address  create new account or create an account with a social network join with facebook join with twitter join with google username or email address  password  loginjoin now  forgot password or login using a social network log in with facebook log in with twitter log in with google dave chiswell  canadian internet registration authority  zoominfocom kymab appoints dr david chiswell as chief executive officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       kymab appoints dr david chiswell as chief executive officer tweet 6  am   life sciences jobs     bullet newest jobs  last 2 hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs cambridge uk  march 6 kymab the cambridgebased antibodiestomedicines company announced today the appointment of dr david chiswell obe as chief executive officer “ceo” with effect from april 6 dr chiswell has occupied the position as kymab interim ceo since early  having been appointed chairman in september  dr chiswell will step down from his role as chairman and dr tim rink will take the role of lead director with effect from april dr tim rink lead director of kymab said “i am delighted with dave’s appointment as ceo dave has an outstanding track record and experience in antibody development and building biotech companies he was instrumental in the development of the world’s best selling antibody abbvie’s humira® adalimumab which was launched in  and has annual sales in excess of  billion” dr david chiswell ceo of kymab commented “i have spent one of the most satisfying years of my career as interim ceo working closely with the excellent team at kymab i believe kymab has all the tools needed to enable it to become a truly successful major biotech company our kymouse® platform has already generated an enviable product pipeline of human monoclonal antibodies which we will continue to expand we attracted high quality investors woodford malin alongside the wellcome trust and the bill  melinda gates foundation in our us million series b fund raise one of the largest preclinical rounds in uk biotech we have established major partnerships such as novo nordisk and the us cancer hospital md anderson i am very pleased to be taking the helm on a permanent basis at a time when we are commencing our clinical trial programmes” dr chiswell has over  years’ experience in the biotechnology industry having cofounded cambridge antibody technology cat in  serving as ceo from  to  cat listed on the london stock exchange in april  and nasdaq in june  and was subsequently sold to astrazenca where it forms an important part of its biopharmaceutical franchise since leaving cat in  he has focused on the development of earlystage biotechnology companies having previously served as a director of arakis nonexecutive chairman of sosei arrow therapeutics and daniolabs and as ceo of nabriva therapeutics  to  dr chiswell currently serves as chairman of albireo pharma and is a director of nabriva therapeutics he is a past chairman of the uk bioindustry association bia and in  he was awarded the most excellent order of the british empire obe by her majesty the queen for services to the biotechnology industry for further information contact kymab david chiswell chief executive officer anne hyland chief financial officer tel  22   email mediakymabcom hume brophy mary clark supriya mathur and hollie vile tel  7 62 6 email kymabhumebrophycom notes to editors about kymab kymab is a leading biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary kymouse antibody platform kymouse has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens selecting from a broad diversity of fully human antibodies assures the highest probability of finding that rare drug candidate with bestinclass characteristics the kymouse naturally matures these molecules to highly potent drugs obviating the need for further timeconsuming modifications kymab is using the platform for its internal drug discovery programmes and in partnership with pharmaceutical companies kymab commenced operations in  and has raised over usm of equity financing which includes m series b financing it was founded by prof allan bradley who is the chief technology officer and has an experienced management team with a successful track record in drug discovery and development and has numerous therapeutic antibody programmes in immuneoncology autoimmunity hematology infectious disease and other areas httpwwwkymabcom read at biospacecom related news kymab succeeds in revoking regeneron regn’s uk velocimmune patents horizon pharma hznp raises ceos pay fold to  million kymab and md anderson cancer center announce strategic partnership in immunooncology research  development why nancy reagan mattered to medical innovation kymab implements genedata biologics for highthroughput antibody discovery glaxosmithkline gsk ceo sir andrew witty to step down in  kymab pulls in  million to speed up antibody pipeline exsanofi genzyme sny exec to head vedanta biosciencess rd at new cambridge site kymab biotech company that is one to watch tonix pharma tnxp ceo toured midtown to raise cash please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • kymab   • biotechpharma  personnel                 albireo » board of directors menu board of directors david chiswell phd chairman of the board albireo chief executive officer kymab after a career as a research scientist in both the united kingdom and the united states and nine years working in scientific management at amersham international david chiswell cofounded cambridge antibody technology cat and served as its ceo for several years in addition to albireo dr chiswell is currently ceo of kymab ltd he was previously chairman of the uk’s bioindustry association bia and remains on its board in  dr chiswell was awarded the obe by hm queen for services to the biotechnology industry julia r brown  julia brown has held a variety of executive positions over her year career in the pharmaceutical industry including as executive vice president and advisor to the ceo of amylin pharmaceuticals inc and executive vice president of dura pharmaceuticals inc previously she spent over 2 years with eli lilly and company in progressively senior roles including vice president of ivac corporation and general manager of its vital signs division and vice president of worldwide marketing for hybritech julia is an experienced director having served previously on the boards of directors of eight drug development companies and as chairperson of the corporate directors forum she is chair emerita of the uc san diego foundation and a member of the board of two industry associations julia earned her undergraduate degree from louisiana tech university and a master’s degree from harvard michael gutch phd chief business officer and chief financial officer entasis therapeutics mike gutch is currently chief business officer and chief financial officer at entasis therapeutics prior to entasis he served as an executive director within astrazeneca’s corporate development group having responsibility for mergers and acquisitions divestments and strategic equity investments previously dr gutch had experience as both a corporate and private venture capital investor as a managing director of medimmune ventures a director with hig bioventures and a principal with lilly ventures the corporate venture capital arm of eli lilly  company while at eli lilly dr gutch was also in the corporate financing and investment banking group where he focused on mergers and acquisitions and licensing transactions dr gutch earned his phd in cellular and molecular pathology from the state university of new york at stony brook and was a postdoctoral research fellow at both ucsf and the cold spring harbor laboratories he earned his mba in finance from indiana university mike also serves as a board director of phasebio pharmaceuticals entasis therapeutics and is a member of the board of directors for southeast bio a member of the johns hopkins alliance for science  technology development and the emory university new venture advisory board heather preston md partner  managing director tpg biotech heather preston is managing director at tpg biotech prior to joining tpg biotech in  dr preston worked in investment banking at jp morgan partners served as an entrepreneurinresidence with new enterprise associates and was a leader of the pharmaceutical and medical products consulting practice at mckinsey  co she has an undergraduate degree in biochemistry from the university of london a medical degree from the university of oxford and a postdoctoral fellowship in molecular biology at the dana farber cancer institute harvard university she completed her training in internal medicine at the massachusetts general hospital and then subspecialized in gastroenterology and hepatology at university of california san francisco during her academic career dr preston was the recipient of a fulbright scholarship a fulbright cancer research scholarship a harlech scholarship and a science and engineering research council postdoctoral fellowship award in addition to albireo dr preston serves on the board of directors of alder biotherapeutics nasdaq aldr and numerous private companies davey s scoon  davey scoon’s business career has included senior executive positions in finance and administration at tom’s of maine inc sunlife financial us and liberty funds group of boston formerly colonial management as well as serving as a cpa with price waterhouse  company he is currently chairman of the board of trustees for allianz global investors and a director and chairman of the audit committee of amag pharmaceuticals inc among other roles he previously served as nonexecutive chairman of tufts health plan davey is also an adjunct professor teaching accounting at the university of wisconsinmadison he earned an mba from harvard business school and a bba in business administration from the university of wisconsin denise scotsknight phd ceo and cofounder mereo biopharma denise scotsknight is ceo and cofounder of mereo biopharma she is also managing partner for phase partners formerly known as phase ventures where she has been responsible for its investment activities since  prior to joining phase dr scotsknight was an investment manager at rothschild asset management and also held senior management positions in rd and strategic consulting in addition to albireo she serves on the board of directors of oncomed pharmaceuticals dr scotsknight holds a phd and bsc hons from birmingham university and was a fulbright scholar at the university of california berkeley ron cooper president and chief executive officer ron cooper albireo’s first president and ceo is a global pl leader with a track record of growing businesses brands and organizations in the us and europe for over 2 years ron worked in five different countries and held positions of increasing responsibility in sales marketing and general management with bristolmyers squibb culminating in his role as president of europe where he was responsible for over  countries with sales exceeding  billion while at bms ron played a leadership role in several product successes including abilify® avapro® atripla® eliquis® orencia® pravachol® plavix® reyataz® sustiva® sprycel® and yervoy® ron has successfully completed more than a dozen business development deals including the creation of the first single tablet hivaids regimen partnership he is a graduate of st francis xavier university in canada albireo homepage menu this site uses cookies to give you the best possible experience learn more dave chiswell appointed kymab ceo – kymab news dave chiswell appointed kymab ceo source kymab ltd dave chiswell takes on and relishes the permanent ceo role after one of the most satisfying years of my career as interim ceo dr david chiswell obe has been appointed as kymabs chief executive officer with effect from april 6 dr chiswell has acted as interim ceo since early  having been appointed chairman in september  dr tim rink will take the role of lead director with effect from april dr chiswell has an enviable record in the industry having worked at amersham founded cambridge antibody technology in  been chair of the uks bioindustry association and served seven other biotech companies as chairman or director i am delighted with daves appointment as ceo dave has an outstanding track record and experience in antibody development and building biotech companies said dr rink he was instrumental in the development of the world’s best selling antibody abbvies humira® adalimumab which was launched in  and has annual sales in excess of  billion i have spent one of the most satisfying years of my career as interim ceo working closely with the excellent team at kymab said dr chiswell i believe kymab has all the tools needed to enable it to become a truly successful major biotech company our kymouse® platform has already generated an enviable product pipeline of human monoclonal antibodies which we will continue to expand we attracted high quality investors woodford and malin alongside the wellcome trust and the bill  melinda gates foundation in our us million series b fund raise one of the largest preclinical rounds in uk biotech we have established major partnerships such as novo nordisk and the us cancer hospital md anderson i am very pleased to be taking the helm on a permanent basis at a time when we are commencing our clinical trial programmes dr chiswell has over  years experience in the biotechnology industry having cofounded cambridge antibody technology cat in  serving as ceo from  to  cat listed on the london stock exchange in april  and nasdaq in june  and was subsequently sold to astrazenca where it forms an important part of their biopharmaceutical franchise since leaving cat in  he has focused on the development of earlystage biotechnology companies having previously served as a director of arakis nonexecutive chairman of sosei arrow therapeutics and daniolabs and as ceo of nabriva therapeutics  to  dr chiswell currently serves as chairman of albireo pharma and is a director of nabriva therapeutics he is a past chairman of the uk bioindustry association bia and in  he was awarded the most excellent order of the british empire obe by her majesty the queen for services to the biotechnology industry share posted  mar 6 categories commentary feature investment ip news news partnership personnel product news rd news back to news articles find out which events well be attending this year view events david chiswells phone  address  peoplebyname contact login home people alphabetically c chiswell david chiswell people directory with over  names record id 66david l chiswell sheppardnorth augusta sc 26age  born may 7 background check  available record id 6667david s chiswell7 woodsmanmilton fl age  born dec  background check  available record id 666david s chiswell2 kingston ridgecary nc  67background check  available record id 666david b chiswell2 kingston ridgecary nc age  born nov  67background check  available record id 76david chiswell pace lnmilton fl background check  available record id 726david l chiswell sheppard rdnorth augusta sc 26age  born may 7 background check  available record id 7david l chiswell sheppard drnorth augusta sc 26age  born may 7 background check  available record id 7david b chiswell las flores drnipomo ca age 7 born may 6background check  available record id 76david b chiswell2 kingston ridge rdcary nc age 7 born may 6 67background check  available record id 722david s chiswell7 woodsman drmilton fl age  born dec  background check  available record id 766david chiswell pace lnmilton fl background check  available record id 762david b chiswell las flores drnipomo ca age 7 born may 6background check  available record id 76david b chiswell2 kingston ridge rdcary nc age 7 born may 6 67background check  available record id 762david l chiswell sheppard rdnorth augusta sc 26age  born may 7 background check  available record id 76david l chiswell sheppard drnorth augusta sc 26age  born may 7 background check  available record id 76david s chiswell7 woodsman drmilton fl age  born dec  background check  available record id 77david chiswell pace lnmilton fl background check  available record id 77david b chiswell las flores drnipomo ca age 7 born may 6background check  available record id 77david b chiswell2 kingston ridge rdcary nc age 7 born may 6 67background check  available record id 7david l chiswell sheppard drnorth augusta sc 26age  born may 7 background check  available record id 76david l chiswell sheppard rdnorth augusta sc 26age  born may 7 background check  available record id 7david s chiswell7 woodsman drmilton fl age  born dec  background check  available record id 7david chiswell pace lnmilton fl background check  available record id 76david b chiswell las flores drnipomo ca age 7 born may 6background check  available record id 76david b chiswell2 kingston ridge rdcary nc age 7 born may 6 67background check  available record id 7david l chiswell sheppard rdnorth augusta sc 26age  born may 7 background check  available record id 76david l chiswell sheppard drnorth augusta sc 26age  born may 7 background check  available record id 76david s chiswell7 woodsman drmilton fl age  born dec  background check  available     72 total records available tweet testimonials read testimonials from real customers who already used our services read more webmasters earn 7 commission on every sale you drive to our website weekly payouts read more mobile version visit us from your smart phone anywhere you are read more recent lookups check out the most recent reverse phone lookups on peoplebynamecom read more home mobile version phone directory people directory remove information terms of service privacy policy affiliate program about us member login frequently asked questions contact us testimonials careers product  services volume discounts site map  peoplebyname all rights reserved